Introduction
Several studies have shown that detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia (ALL) is clinically relevant. [1] [2] [3] [4] [5] [6] [7] Detection of MRD can be used to evaluate early treatment response, and thereby allows the identification of low-risk and high-risk patients who may profit from therapy reduction or therapy intensification, respectively. [1] [2] [3] [4] Furthermore, detection of MRD just prior to stem cell transplantation has been shown to be an important prognostic factor. 5, 6 So far, mainly bone marrow (BM) samples have been used for large-scale MRD studies. Regular collection of BM aspirates is however a traumatic experience for children, especially during the last phases of therapy and after the end of treatment. 8 It would therefore be beneficial if BM sampling could be replaced by peripheral blood (PB) sampling.
Some 15 years ago, our immunophenotyping data already suggested that MRD levels are similar in paired BM-PB samples of children with T-ALL. 9, 10 At that time, sensitive and quantitative detection of MRD in T-ALL was possible by double-immunofluorescence stainings of terminal deoxynucleotidyl transferase (TdT) and a T cell marker (eg CD5 and CD7), as such double-positive cells are normally exclusively found in the thymus. Therefore, the presence of a TdT-positive T cell in PB or BM is indicative of the presence of leukemic cells. [9] [10] [11] In precursor-B-ALL, sensitive and quantitative MRD analysis was initially hampered by the presence of normal precursor-B cells. In normal BM of children, up to 15% of cells are precursor-B cells, whereas during BM regeneration (such as after stem cell transplantation or after chemotherapy courses) precursor-B cells may even comprise up to 50% of cells. 9, [12] [13] [14] [15] Also in normal PB, precursor-B cells are found, although at low frequencies (up to 0.4%). 9, 15 Consequently, 15 years ago no reliable comparison could be made between MRD levels in BM and PB samples of precursor-B-ALL patients. However, recent immunophenotyping data of Campana and CoustanSmith suggest that MRD levels are higher in BM than in PB in at least some precursor-B-ALL patients. 11, 16 A few years ago, real-time quantitative PCR (RQ-PCR) technology became available. 17 Using the junctional regions of immunoglobulin (Ig) and/or T cell receptor (TCR) gene rearrangements as 'DNA fingerprints' of the leukemic cells, RQ-PCR analysis allows the sensitive and quantitative analysis of MRD in both precursor-B-ALL and T-ALL. 6 ). By applying RQ-PCR analysis of Ig/TCR gene rearrangements, it therefore now becomes possible to reliably investigate whether BM samples can be replaced by PB samples in precursor-B-ALL patients. A recent study suggested that molecular relapse in precursor-B-ALL can be detected via PB sampling in a sensitive and timely fashion, as increased numbers of leukemic cells could be detected in PB during the 4-6 weeks prior to relapse. 22 However, no comparative analyses of MRD levels in BM and PB samples were made. In this study, we analyzed MRD levels in 681 pairs of BM and PB samples of children with precursor-B-ALL (n ϭ 62) or T-ALL (n ϭ 22) by RQ-PCR analysis. Additionally, we evaluated the MRD results obtained earlier of 321 paired BM-PB samples of 26 T-ALL patients, as deter-mined by T cell marker/TdT double-immunofluorescence stainings.
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Materials and methods
Patients
Sixty-two children with precursor-B-ALL and 22 children with T-ALL were included in the RQ-PCR-based MRD study. All 84 patients were treated according to the ALL-8 or ALL-9 protocol of the Dutch Childhood Leukemia Study Group (DCLSG).
3 BM and PB samples were collected at diagnosis and during follow-up. In total, 532 paired BM-PB follow-up samples were analyzed in the 62 precursor-B-ALL patients (mean, 8.6 samples/patient) and 149 paired BM-PB follow-up samples were analyzed in the 22 T-ALL patients (mean, 6.8 samples/patient). Mononuclear cells (MNC) were separated and DNA was isolated as described previously. 23 Previously obtained immunophenotypic MRD data of 321 paired BM-PB follow-up samples from an additional 26 T-ALL patients were evaluated as well. These 26 T-ALL patients were diagnosed between 1983 and 1990 and treated according to the DCLSG ALL-6 or ALL-7 protocols. 24 
Immunophenotyping
Immunophenotyping was performed as described previously. 9, 25 Briefly, MNC were stained with a T cell marker (CD1, CD3, CD5 and/or CD7), the choice of the T cell marker being partly dependent on the immunophenotype of the T-ALL at diagnosis. After washing and staining with tetramethylrhodamine isothiocyanate-conjugated goat anti-mouse Ig antiserum (Nordic Immunological Laboratories, Tilburg, The Netherlands), two cytocentrifuge preparations (each containing a mean of 30 000 cells) were made per T cell marker labeling. After fixation in methanol (30 min at 4ºC), the cytocentrifuge preparations were stained with a rabbit anti-TdT antiserum and a fluoresceine isothiocyanate-conjugated goat anti-rabbit Ig antiserum (Supertech, Bethesda, MD, USA). Using immunofluorescence microscopy (Carl Zeiss, Oberkochen, Germany), the slides were evaluated for the frequency of TdT-positive cells and for the expression of a T cell marker by the TdT + cells. Generally, two different T cell marker/TdT double-labelings were performed per cell sample and two cytocentrifuge preparations were made for each T cell marker/TdT double-labeling. Consequently, approximately 60 000 to 120 000 MNC were evaluated per cell sample. 25 
RQ-PCR analysis of Ig/TCR gene rearrangements
To detect IGH, IGK-Kde, TCRG, or TCRD gene rearrangements or TAL1 deletions at diagnosis, PCR amplification, heteroduplex analysis, and sequencing were performed as described previously. 6, 21, 26, 27 Allele-specific oligonucleotides, at least in part positioned in the junctional region, were designed and used in combination with germline TaqMan probes and germline reverse primers for sensitivity testing. 6, 19, 21 To correct the MRD levels in follow-up samples for the quantity and quality of DNA, RQ-PCR analysis of the albumin gene was used. 18 
Leukemia
Statistical analysis
Statistical analyses were performed using log-transformed data and SPSS 9.0.0 software. The Wilcoxon signed rank test was used to determine whether MRD levels in paired BM-PB samples differed. The Spearman's correlation coefficient (r s ) was determined to assess the correlation between MRD levels in paired BM-PB samples. For this correlation analysis, only paired BM-PB samples with detectable MRD levels in at least one compartment were included. MRD-positive follow-up samples with MRD levels below the reproducible sensitivity (ie no accurate quantification possible) were assumed to have an MRD level one log below the reproducible sensitivity. If no MRD was detected in one of the paired BM-PB samples, a value two logs below the reproducible sensitivity was used. A P value less than 0.05 was considered to be statistically significant.
Results and discussion
We first re-evaluated the immunophenotypic MRD data available from 26 T-ALL patients obtained earlier. The applied immunophenotypic MRD technique reached a sensitivity of at least 10 −4 . 9 Analysis of 321 paired BM-PB samples showed detectable MRD levels in BM and/or PB in 72 pairs (obtained from 23 of the 26 patients). In 50 pairs MRD was detected in both BM and PB, whereas in the remaining samples very low levels of MRD were detected in BM (n ϭ 15) or PB (n = 7) only. MRD levels in the 72 MRD-positive paired BM-PB samples strongly correlated (r s = 0.822, P Ͻ 0.01; Figure 1 ), although the mean MRD level in PB was about half log lower than in BM.
Figure 1
MRD levels in paired BM and PB samples from T-ALL patients analyzed by immunophenotyping. MRD levels in 321 paired BM and PB samples obtained from 26 T-ALL patients (including four patients with a central nervous system relapse) were analyzed by immunophenotyping using T cell marker/TdT double-stainings. 9 A strong correlation between MRD levels in BM and PB was observed (r s = 0.822; P Ͻ 0.01). Closed circles, samples taken within 3 months after diagnosis (during and just after induction therapy); open circles, samples taken more than 3 months after diagnosis. Neg, MRD negative. (n = 4), 10 −4 (n = 15), and Յ10 −5 (n = 7). In four patients, MRD was analyzed by two PCR targets; for each sample the highest MRD level was used for statistical analysis.
Out of the 149 analyzed paired BM-PB samples, 67 pairs (from 14 different patients) contained detectable MRD levels in BM and/or PB (Figure 2a) . In 47 out of these 67 pairs, MRD was detected in both BM and PB, whereas in the remaining pairs MRD was detected in BM (n = 11) or PB (n = 9) only. In the latter 20 pairs, MRD levels were very low and outside the reproducible range of the RQ-PCR analysis (Figure 2a) . In 82 pairs MRD could not be detected, either in BM or in PB. These data show that MRD detection in BM and PB of T-ALL patients gives concordant results in the vast majority of samples (Ͼ85%). Furthermore, as shown in Figure 2a , also the level of MRD in BM and PB was very comparable and strongly correlated (r s = 0.849; P Ͻ 0.01), irrespective of the follow-up time point (Ͻ3 months or Ͼ3 months). The combined immunophenotyping and RQ-PCR results clearly demonstrate that MRD analysis of BM and PB gives comparable results in T-ALL patients, both with respect to MRD positivity/negativity, as well as to MRD levels.
We then evaluated MRD levels in paired BM-PB samples from 62 precursor-B-ALL patients by RQ-PCR analysis of Ig/TCR gene rearrangements. Twenty-two IGH, 20 IGK-Kde, 15 TCRG, and 21 TCRD gene rearrangements were used as MRD-PCR targets with sensitivities varying between 10 −3 (n = 22), 10 −4 (n = 44), and 10 −5 (n = 12). In 16 patients, two PCR targets were used for the MRD analysis; for each sample the highest MRD level was used for statistical analysis.
Out of the 532 analyzed paired BM-PB samples, 425 pairs were MRD-negative in both BM and PB, but in 107 pairs (from 39 different patients) MRD was detected in BM and/or PB (Figure 2b ). In 47 of these 107 pairs, MRD was only detected in BM and not in the corresponding PB sample, while in 12 BM-PB pairs only the PB samples were positive at very low levels (р10 −4 ). In the 48 pairs with detectable MRD in both BM and PB, the MRD levels in the BM samples were significantly higher than the MRD levels in the corresponding PB samples (Figure 2b ; P Ͻ 0.01); the difference ranged from one to more than 1000-fold (Figure 2b) .
It has been suggested that MRD levels in PB are one to 1.5 log lower than in BM, 28 but this is not confirmed by our data. Instead, our data as well as Campana's preliminary data, 11, 16 show a highly variable ratio between MRD levels in BM and PB, ranging from one to more than 1000 (Figure 2b ). This implies that no simple straightforward relationship exists between MRD levels in paired BM and PB samples of precursor-B-ALL patients, particularly not at later time points (Ͼ3 months). Consequently, PB sampling cannot easily replace BM sampling for MRD detection in precursor-B ALL patients.
Our data are obtained from a relatively small group of 110 patients (62 precursor-B-ALL and 48 T-ALL), with a limited number of MRD-positive paired BM-PB samples (246 pairs). Nevertheless, the data show that for the total group of T-ALL patients MRD monitoring is possible by usage of PB samples, whereas for the total group of precursor-B-ALL patients BM samples are required for reliable MRD analysis. We cannot exclude the existence of small subgroups of T-ALL patients with selective homing to the BM compartment, or small subgroups of precursor-B-ALL patients with high dissemination to MRD levels in paired BM and PB samples from T-ALL and precursor-B-ALL patients analyzed by RQ-PCR analysis. (a) MRD levels in 149 paired BM and PB samples from 22 T-ALL patients were analyzed by RQ-PCR analysis using TCR gene rearrangements and TAL1 deletions. MRD detection in BM and PB gave concordant results in the vast majority of samples and a strong correlation between MRD levels in BM and PB was observed (r s = 0.849; P Ͻ 0.01). (b) MRD levels in 532 paired BM and PB samples from 62 precursor-B-ALL patients were analyzed by RQ-PCR analysis using Ig/TCR gene rearrangements. MRD levels in BM were significantly higher than in the corresponding PB samples (P Ͻ 0.01). Furthermore, the ratio between MRD levels in BM and PB was highly variable, ranging from one to more than 1000. Closed circles, samples taken within 3 months after diagnosis (during and just after induction therapy); open circles, samples taken more than 3 months after diagnosis. Pos, MRD-positive but no quantification possible due to very low MRD levels (specific amplification outside reproducible range); 19, 21 Neg, MRD negative.
PB. For recognition of such small subgroups, paired BM-PB samples of very large numbers of ALL patients need to be investigated. These investigations might also reveal whether PB monitoring of early treatment response (Ͻ3 months) is clinically relevant in precursor-B-ALL patients (Figure 2b )
Our quantitative MRD data are in line with the fact that precursor-B-ALL are of BM origin, which probably explains the higher MRD levels in BM than in the corresponding PB samples. T-ALL are, however, of thymic origin and show a highly disseminating character, resulting in comparable MRD levels in BM and PB samples. 9, 10 In conclusion, our data clearly show that in T-ALL BM sampling might be replaced by PB sampling. This is in contrast to precursor-B-ALL, where BM sampling is required for MRD monitoring because the MRD levels in PB do not reflect the MRD levels in BM, also not in the case of high MRD levels in BM.
